Future studies would involve in-depth isotope tracing studies on breast cancer cell lines and tissues to determine the contributions of glucose and glutamine to CCL2/CCR2- and MET-mediated metabolism during DCIS progression. The gene discussed is MET; the disease is breast carcinoma.